PEDEVCO CORP. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PEDEVCO CORP. on January 21, 2021, covering events that occurred on January 19, 2021. The company is incorporated in Texas and its common stock trades on the NYSE American under the symbol "PED".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on equity compensation awards.
Material Changes and Events
On January 19, 2021, the Board of Directors approved the issuance of equity awards under the Amended and Restated 2012 Equity Incentive Plan as part of the annual compensation review. The total awards included:
- Restricted Stock: An aggregate of 940,000 shares of restricted common stock.
- Stock Options: Options to purchase an aggregate of 550,000 shares of restricted common stock.
Specific Allocations:
- Simon G. Kukes (CEO): 300,000 restricted shares.
- J. Douglas Schick (President): 250,000 restricted shares.
- Clark R. Moore (EVP, General Counsel, Secretary): 250,000 restricted shares.
- Paul Pinkston (Chief Accounting Officer): 140,000 restricted shares.
- Simon G. Kukes' Wife (Employee): Options to purchase 10,000 shares with an exercise price of $1.39 per share.
- Other Non-Executive Employees: Options to purchase 540,000 shares with an exercise price of $1.39 per share.
All awards are subject to a three-year vesting schedule (1/3 annually) contingent upon continued service.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, management commentary on operations, or specific risk factors. The primary contingency noted is that all equity awards are subject to the recipients' continued service to the company on the vesting dates.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2012 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of PEDEVCO stock relative to the $1.39 exercise price for the newly granted options.
- Review the vesting schedules to understand the timeline for potential dilution.
- Check subsequent filings for any changes in executive compensation or departures of the named officers.